Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Enabling collaborative governance of medical AI

Nature Machine Intelligence volume 5, pages 821–823 (2023)Cite this article

Subjects

Medical artificial intelligence needs governance to ensure safety and effectiveness, not just centrally (for example, by the US Food and Drug Administration) but also locally to account for differences in care, patients and system performance. Practical collaborative governance will enable health systems to carry out these challenging governance tasks, supported by central regulators.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wong, A. et al. JAMA Internal Med. 181, 1065–1070 (2021).

    Article  Google Scholar 

  2. Price II, W. N. SMU Sci. Tech. L. Rev. 25, 3–21 (2022).

  3. Wong, A. et al. JAMA Netw. Open 4, e2135286 (2021).

    Article  Google Scholar 

  4. Obermeyer, Z., Powers, B., Vogeli, C. & Mullainathan, S. Science 366, 447–453 (2019).

    Article  Google Scholar 

  5. Price II, W. N., Gerke, S. & Cohen, I. G. J. Am. Med. Assoc. 322, 1765–1766 (2019).

  6. Sendak, M. P., Gao, M., Brajer, N. & Balu, S. NPJ Digit. Med. 3, 1–4 (2020).

    Article  Google Scholar 

  7. Panch, T. et al. PLoS Digit. Health 1, e0000040 (2022).

    Article  Google Scholar 

  8. Sendak, M. P. et al. Proc. Mach. Learn. Res. 182, 1–19 (2022).

    Google Scholar 

  9. Sendak, M. P., Balu, S. & Schulman, K. A. Appl. Clin. Inform. 8, 826–831 (2017).

    Article  Google Scholar 

  10. Bedoya, A. D. et al. J. Am. Med. Inform. Assoc. 29, 1631–1636 (2022).

    Article  Google Scholar 

  11. Wiens, J. et al. Nat. Med. 25, 1337–1340 (2019).

    Article  Google Scholar 

  12. Sendak, M. P. et al. JMIR Med. Inform. 8, e15182 (2020).

    Article  Google Scholar 

  13. Finlayson, S. G. et al. N. Engl. J. Med. 385, 283–286 (2021).

    Article  Google Scholar 

  14. Kim, J. Y. et al. Proc. 2023 ACM Conference on Fairness, Accountability, and Transparency 1396–1417 (2023).

  15. Sendak, M. P., Price II, W. N. & Balu, S. STAT https://go.nature.com/3pKJNF3 (2022).

  16. US FDA. https://go.nature.com/3negsku (2022).

Download references

Acknowledgements

This research is funded in part by the Gordon and Betty Moore Foundation, through grant GBMF10849 to Duke University to support the work of Health AI Partnership; and in part by the Novo Nordisk Foundation, through grant NNF17SA027784 for a scientifically independent Collaborative Research Programme in Biomedical Innovation Law.

Author information

Authors and Affiliations

  1. University of Michigan Law School, Ann Arbor, MI, USA

    W. Nicholson Price II

  2. Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen Faculty of Law, Copenhagen, Denmark

    W. Nicholson Price II

  3. Duke Institute for Health Innovation, Durham, NC, USA

    Mark Sendak & Suresh Balu

  4. University of Michigan Medical School, Ann Arbor, MI, USA

    Karandeep Singh

Authors
  1. W. Nicholson Price II
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Sendak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suresh Balu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Karandeep Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Nicholson Price II.

Ethics declarations

Competing interests

W.N.P. declares no competing interests. M.P.S. is a co-inventor of intellectual property licensed by Duke University to Clinetic, Inc., KelaHealth, Inc. and Cohere-Med, Inc. M.P.S. holds equity in Clinetic, Inc. S.B. is a co-inventor of intellectual property licensed by Duke University to Clinetic, Inc. and Cohere-Med, Inc. K.S.’s institution receives grant funding from the US National Institute of Diabetes and Digestive and Kidney Diseases, Blue Cross Blue Shield of Michigan and Teva Pharmaceuticals for unrelated work. K.S. previously served on a scientific advisory board for Flatiron Health and received consulting fees.

Peer review

Peer review information

Nature Machine Intelligence thanks Vasiliki Rahimzadeh for their contribution to the peer review of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Price, W.N., Sendak, M., Balu, S. et al. Enabling collaborative governance of medical AI. Nat Mach Intell 5, 821–823 (2023). https://doi.org/10.1038/s42256-023-00699-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42256-023-00699-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing